Tag: asset

RENO, Nev., June 26, 2026 (GLOBE NEWSWIRE) -- Employers Holdings, Inc. (the “Company”) (NYSE:EIG) will release its second quarter 2026 financial results after market close on Wednesday, July 29, 2026, after which these materials will be available on the Company’s website at www.employers.com through the “Investors” link.

Ji'an, Jiangxi, China, June 26, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company has entered into a share purchase agreement to acquire 100% of the issued shares of Best Praise International Limited (“Best Praise”), a company that holds five patents in China with potential applications in pharmaceutical development, for a total purchase price of US$10,751,000, payable in the form of 4,376,552 Class A ordinary shares of the Company.

Dubai, June 26, 2026 (GLOBE NEWSWIRE) -- Eldorado Drilling Limited (“Eldorado”) and Vantage Drilling International Ltd. (“Vantage”) today announced the completion of Eldorado’s acquisition of Vantage by merger, pursuant to which an indirect subsidiary of Eldorado merged with and into Vantage, with Vantage surviving as an indirect subsidiary of Eldorado as of 3.00 p.m. Bermuda time on June 26, 2026 (the “Closing”).

Vilnius, Lithuania, June 26, 2026 (GLOBE NEWSWIRE) --

AB Tewox, managed by Lords LB Asset Management, continues to expand its retail real estate portfolio in Poland with the acquisition of a retail park in Nysa that was opened in November 2025.

London, United Kingdom, June 26, 2026 (GLOBE NEWSWIRE) --

BulkQuant, a fully managed AI trading robot platform, is expanding its automated trading ecosystem to help retail investors explore structured trading strategies across cryptocurrency, forex, and stock market environments.

Oslo, 26 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. This concludes the previously communicated wrap-up phase of the UV1 cancer vaccine programme and Zelluna now considers the programme closed.

Company outlines its compliance-first framework for tokenized securities as the U.S. regulatory environment for digital assets continues to evolve.